ReviewNature reviews. Disease primers2026
Methicillin-resistant Staphylococcus aureus.
Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of antimicrobial-resistant infection worldwide. The spectrum of diseases caused by MRSA range from uncomplicated skin and soft-tissue infections to life-threatening invasive infections such as bacteraemia, pneumonia, osteomyelitis and endocarditis. MRSA commonly colonizes the skin and mucosal surfaces as an asymptomatic commensal but can transition to an invasive pathogen when host barriers are disrupted or immune defences are compromised. The shift from commensal to pathogen is facilitated by a broad repertoire of virulence factors that promote adhesion, immune evasion, tissue invasion and persistence within host tissues. Despite the development of several new antibiotics with activity against MRSA, clinical outcomes during invasive infections are poor, with many patients experiencing persistent or recurrent infection. Strategies to prevent MRSA infection include infection control measures, screening and targeted decolonization approaches; however, the effectiveness of these interventions varies and often depends on local MRSA prevalence and epidemiological context. Understanding the epidemiology, pathogenesis and clinical management of MRSA remains essential to guide effective prevention and treatment strategies.
Indexed as
Identifiers
42595754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.